Association of Genetic Variation in the MET Proto-Oncogene With Schizophrenia and General Cognitive Ability

被引:31
|
作者
Burdick, Katherine E. [1 ]
DeRosse, Pamela
Kane, John M.
Lencz, Todd
Malhotra, Anil K.
机构
[1] Zucker Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Dept Psychiat Res, Glen Oaks, NY 11004 USA
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2010年 / 167卷 / 04期
关键词
HEPATOCYTE GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; INTERNEURON DEVELOPMENT; CANCER-RISK; AUTISM; SUSCEPTIBILITY; DISRUPTION; MEDICATION; PARENTS; PATHWAY;
D O I
10.1176/appi.ajp.2009.09050615
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Despite increased exposure to cancer risk factors, several studies have demonstrated a lower incidence of cancer in schizophrenia patients than in the general population. Lower cancer rates in first-degree relatives of schizophrenia patients suggest that the inverse relationship between cancer and schizophrenia may be related to genetic factors. Few studies of schizophrenia have focused on cancer-related genes. The MET proto-oncogene is primarily linked to tumor metastasis, but MET is also involved in neurodevelopment and influences risk for autism. Thus, MET may be of particular interest as a candidate gene for neuropsychiatric diseases with a developmental etiology, including schizophrenia. Method: The authors examined the relationship between 21 single-nucleotide polymorphisms in MET and schizophrenia in 173 Caucasian patients and 137 comparison subjects. They then genotyped a second independent sample (107 patients and 112 comparison subjects) for replication. Finally, they tested for MET's effects on general cognitive ability (g). Results: In the initial cohort, the authors identified four haplotype blocks and found one block to be globally associated with schizophrenia. In block 3, the most common haplotype was over-represented in comparison subjects (frequency, 47%) relative to schizophrenia patients (frequency, 33%) (p=4.0x10(-4); odds ratio=0.56). The authors replicated the block 3 finding in the second sample with similar frequencies: 46% in comparison subjects and 36% in schizophrenia patients (p=0.03; odds ratio=0.66). Moreover, the protective haplotype was associated with a higher g in the combined comparison sample. Conclusions: These data suggest that MET variation influences schizophrenia risk and neurocognition, supporting a neurodevelopmental role across CNS-relevant phenotypes. These results add to the growing evidence suggesting an intriguing relationship between cancer-related genes and schizophrenia susceptibility.
引用
收藏
页码:436 / 443
页数:8
相关论文
共 50 条
  • [1] CHARACTERIZATION OF THE MOUSE MET PROTO-ONCOGENE
    CHAN, AML
    KING, HWS
    DEAKIN, EA
    TEMPEST, PR
    HILKENS, J
    KROEZEN, V
    EDWARDS, DR
    WILLS, AJ
    BROOKES, P
    COOPER, CS
    ONCOGENE, 1988, 2 (06) : 593 - 599
  • [2] Candidate Gene Studies in the GWAS Era: The MET Proto-Oncogene, Neurocognition, and Schizophrenia
    Cannon, Tyrone D.
    AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (04): : 369 - 372
  • [3] Gene structure of the human MET proto-oncogene
    Fuh-Mei Duh
    Stephen W Scherer
    Lap-Chee Tsui
    Michael I Lerman
    Berton Zbar
    Laura Schmidt
    Oncogene, 1997, 15 : 1583 - 1586
  • [4] Genetic variation in the proto-oncogene SKI and risk for orofacial clefting
    Lu, W
    Volcik, K
    Zhu, HP
    Wen, S
    Shaw, GM
    Lammer, EJ
    Finnell, RH
    MOLECULAR GENETICS AND METABOLISM, 2005, 86 (03) : 412 - 416
  • [5] Gene structure of the human MET proto-oncogene
    Duh, FM
    Scherer, SW
    Tsui, LC
    Lerman, MI
    Zbar, B
    Schmidt, L
    ONCOGENE, 1997, 15 (13) : 1583 - 1586
  • [6] CHROMOSOMAL LOCALIZATION OF THE MET PROTO-ONCOGENE IN THE MOUSE AND CAT GENOME
    DEAN, M
    KOZAK, C
    ROBBINS, J
    CALLAHAN, R
    OBRIEN, S
    VANDEWOUDE, GF
    CYTOGENETICS AND CELL GENETICS, 1987, 46 (1-4): : 605 - 605
  • [7] BIOSYNTHESIS OF THE PROTEIN ENCODED BY THE C-MET PROTO-ONCOGENE
    GIORDANO, S
    DIRENZO, MF
    NARSIMHAN, RP
    COOPER, CS
    ROSA, C
    COMOGLIO, PM
    ONCOGENE, 1989, 4 (11) : 1383 - 1388
  • [8] Novel mutations of the MET proto-oncogene in papillary renal carcinomas
    Schmidt, L
    Junker, K
    Nakaigawa, N
    Kinjerski, T
    Weirich, G
    Miller, M
    Lubensky, I
    Neumann, HPH
    Brauch, H
    Decker, J
    Vocke, C
    Brown, JA
    Jenkins, R
    Richard, S
    Bergerheim, U
    Gerrard, B
    Dean, M
    Linehan, WM
    Zbar, B
    ONCOGENE, 1999, 18 (14) : 2343 - 2350
  • [9] Novel mutations of the MET proto-oncogene in papillary renal carcinomas
    Laura Schmidt
    Kerstin Junker
    Noboru Nakaigawa
    Tracy Kinjerski
    Gregor Weirich
    Maria Miller
    Irina Lubensky
    Hartmut PH Neumann
    Hiltrud Brauch
    Johann Decker
    Cathy Vocke
    James A Brown
    Robert Jenkins
    Stephane Richard
    Ulf Bergerheim
    Bernard Gerrard
    Michael Dean
    W Marston Linehan
    Berton Zbar
    Oncogene, 1999, 18 : 2343 - 2350
  • [10] Induction of c-met proto-oncogene expression at the metastatic site
    Imai, J
    Watanabe, M
    Sasaki, M
    Yamaguchi, R
    Tateyama, S
    Sugano, S
    CLINICAL & EXPERIMENTAL METASTASIS, 1999, 17 (05) : 457 - 462